Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2021 | Percentile | Sector n |
|---|---|---|---|---|
| Akhali Khedva | Pharma | 35.9% | 84th pct | 116 |
| SmartPharm | Pharma | 9.1% | 37th pct | 116 |
| Impexpharm | Pharma | 7.1% | 31st pct | 116 |
| Iberi + | Pharma | 3.7% | 23rd pct | 116 |
| Pharmaceutical House+ | Pharma | -5.9% | 7th pct | 116 |
Percentile is within each company's own sector across the whole FY2021 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2021 | Impexpharm | Pharmaceutical House+ | SmartPharm | Iberi + | Akhali Khedva |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 22.6% | 14.2% | 17.2% | 27.4% | 64.1% |
| EBITDA Margin | 7.1% | -5.9% | 9.1% | 3.7% | 35.9% |
| EBITDAR | 7,748 | 263 | 3,059 | 1,324 | 2,744 |
| EBITDAR Margin | 7.1% | 0.5% | 9.5% | 8.8% | 38.4% |
| EBIT Margin | 3.4% | -6.8% | 9.0% | 3.2% | 32.7% |
| Net Profit Margin | 8.3% | -3.0% | 8.0% | 3.3% | 32.8% |
| Operating Expense % of Sales | 15.4% | 20.1% | 8.1% | 23.8% | 28.2% |
| Returns | |||||
| Return on Assets (ROA) | 10.8% | -4.2% | 23.9% | 6.3% | 28.2% |
| Return on Equity (ROE) | 15.5% | N/A | 35.6% | 10.1% | 47.9% |
| ROIC [EBIT / Invested Capital] | 6.0% | ||||
| -38.7% |
| 54.9% |
| 12.8% |
| 41.1% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 19.9% | 33.6% | 0.0% | 0.0% | 25.8% |
| Debt-to-Equity | 0.29x | -4.45x | 0.00x | 0.00x | 0.44x |
| Debt-to-EBITDA | 2.16x | N/A | 0.00x | 0.00x | 0.84x |
| Equity-to-Assets | 69.8% | -7.6% | 67.0% | 62.0% | 58.8% |
| Net Debt | 2,438 | 12,510 | -1,962 | -1,116 | 799 |
| Cash & Equivalents | 14,283 | 353 | 1,962 | 1,116 | 1,351 |
| Total Debt | 16,722 | 12,864 | N/A | N/A | 2,150 |
| Liquidity & working capital | |||||
| Current Ratio | 6.40x | 1.13x | 2.95x | 2.25x | 5.77x |
| Quick Ratio | 2.74x | 0.60x | 0.97x | 1.20x | 5.77x |
| Cash Ratio | 1.65x | 0.01x | 0.55x | 0.38x | 1.06x |
| Total Current Assets | 55,427 | 36,016 | 10,517 | 6,695 | 7,391 |
| Total Current Liabilities | 8,667 | 31,870 | 3,568 | 2,976 | 1,280 |
| Inventory | 31,696 | 16,941 | 7,070 | 3,114 | N/A |
| Trade Receivables | 4,028 | 6,959 | 1,485 | 1,887 | 1,673 |
| Trade Payables | 7,482 | 27,325 | 3,568 | 2,936 | 896 |
| Net Working Capital | 46,760 | 4,147 | 6,949 | 3,719 | 6,111 |
| Net Working Capital % of Revenue | 42.9% | 7.6% | 21.6% | 24.8% | 85.5% |
| Trade Working Capital | 28,242 | -3,425 | 4,986 | 2,065 | 776 |
| Trade Working Capital % of Revenue | 25.9% | -6.3% | 15.5% | 13.8% | 10.9% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | 2.66x | 2.77x | 3.77x | 3.49x | N/A |
| Days Inventory Outstanding (DIO) | 137.1 | 131.7 | 96.7 | 104.4 | N/A |
| Receivables Turnover | 27.05x | 7.86x | 21.69x | 7.95x | 4.27x |
| Days Sales Outstanding (DSO) | 13.5 | 46.4 | 16.8 | 45.9 | 85.4 |
| Payables Turnover | 11.28x | 1.72x | 7.48x | 3.71x | 2.86x |
| Days Payable Outstanding (DPO) | 32.4 | 212.5 | 48.8 | 98.5 | 127.5 |
| Cash Conversion Cycle | 118.3 days | -34.3 days | 64.7 days | 51.9 days | -42.1 days |
| Asset Turnover | 1.30x | 1.43x | 2.98x | 1.91x | 0.86x |
| Cash flow & dividends | |||||
| Operating Cash Flow | 8,880 | 5,996 | 1,966 | 81 | N/A |
| Free Cash Flow (OCF − Capex proxy) | 2,538 | 4,578 | 1,891 | -299 | N/A |
| Cash Conversion (OCF / EBITDA) | 114.6% | N/A | 67.0% | 14.7% | N/A |
| Dividends Declared | 1,053 | 0 | 260 | N/A | N/A |
| Dividend Payout Ratio | 11.6% | N/A | 10.1% | N/A | N/A |